세계의 대장 표적 약물전달 시장 보고서(2025년)
Colon Targeting Drug Delivery Global Market Report 2025
상품코드 : 1760508
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,632,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,586,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,540,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

대장 표적 약물전달 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 8.3%의 연평균 성장률로 20억 7,000만 달러에 달할 것으로 예상됩니다. 이 예측 기간 동안의 성장은 자극 반응성 및 나노기술 기반 전달 시스템 개발, 위탁 R&D 및 제조 서비스 확대, 규제 당국의 인센티브 제공 및 승인 경로 가속화, 생물학적 제제 및 바이오시밀러의 표적 전달에 기인할 것으로 보입니다. 이 기간 동안 주요 동향으로는 pH 반응성 시스템의 발전, 맞춤형 의료의 통합, 제제 설계에 AI 및 디지털 툴의 활용, 경구용 대장 전달에 대한 관심 증가 등을 들 수 있습니다.

소화기 질환의 유병률 증가는 대장 표적 약물전달 시장의 성장을 촉진할 것으로 예상됩니다. 위, 장 및 관련 장기를 포함한 소화기 계통에 영향을 미치는 위장 질환은 가공식품의 과다 섭취와 낮은 식이섬유 섭취와 같은 건강에 해로운 식습관으로 인해 점점 더 흔해지고 있습니다. 이러한 식습관은 장 건강과 소화를 방해하고 염증성 장질환(IBD)과 같은 질환의 증가로 이어집니다. 대장 표적 약물전달은 약물이 염증 및 감염 부위에 정확하게 방출되어 치료 효과를 높이고 전신 부작용을 최소화하기 위해 사용되고 있습니다. 예를 들어, 2023년 6월 Crohn's and Colitis Canada는 염증성 장질환 환자 수가 2023년 32만 2,600명(인구의 0.8%)에서 2035년 47만 명(인구의 1.1%)으로 증가할 것으로 예측하고 있습니다. 이러한 소화기 질환의 유병률 증가가 대장 표적 약물전달 솔루션에 대한 수요를 촉진하고 있습니다.

대장 표적 약물전달 시장의 기업들은 표적 약물의 방출을 개선하고, 치료 효과를 높이고, 부작용을 줄이기 위한 첨단 솔루션 개발에 주력하고 있습니다. 이러한 혁신 중 하나는 기능성 경구용 제형의 개발로, 상부 소화관에서의 분해로부터 활성 제약 성분(API)을 보호하고 대장에서의 방출 제어를 보장하도록 설계된 기능성 경구용 제형의 개발입니다. 2024년 9월, 독일의 특수화학 제조업체인 Evonik Industries AG는 대장에 경구 약물전달을 가능하게 하는 즉시 충전 가능한 캡슐 기술인 EUDRACAP Functional을 발표했습니다. EUDRACAP Functional은 특정 장내 pH 수준에서만 용해되는 pH 민감성 폴리머를 사용하여 약물이 그대로 대장에 도달할 수 있도록 보장하며, 펩타이드 및 프로바이오틱스와 같은 복잡한 약물의 경구 전달을 지원함으로써 만성 소화기 질환에 대한 환자 친화적인 치료법 개발을 지원하여 보다 높은 정확도와 전신 노출 감소를 실현합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Colon targeting drug delivery refers to a specialized system designed to release therapeutic agents directly in the colon, enhancing treatment effectiveness for local diseases such as inflammatory bowel disease and colorectal cancer. This approach minimizes systemic side effects and improves patient compliance.

The main dosage forms for colon-targeted drug delivery include tablets, capsules, microspheres, nanoparticles, and others. Tablets are solid, compressed forms of medication intended for oral intake. In colon-targeted delivery, these tablets are often coated with materials that prevent dissolution in the stomach or small intestine, ensuring the drug is released specifically in the colon. Various technologies are used in these systems, including pH-sensitive systems, time-dependent systems, microbially triggered systems, pressure-controlled systems, and others. These systems are applied in treating conditions such as inflammatory bowel disease, colorectal cancer, infectious diseases, and more. They are primarily utilized by end users such as hospitals, clinics, research institutes, and other healthcare settings.

The colon targeted drug delivery market research report is one of a series of new reports from The Business Research Company that provides colon targeted drug delivery market statistics, including the colon targeted drug delivery industry's global market size, regional shares, competitors with a colon targeted drug delivery market share, detailed colon targeted drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the colon targeted drug delivery industry. This colon targeted drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The colon targeting drug delivery market size has grown strongly in recent years. It will grow from$1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of colorectal diseases, an increased focus on localized drug delivery, the need for improved patient compliance, and the emergence of biologics and peptides in treatment options.

The colon targeting drug delivery market size is expected to see strong growth in the next few years. It will grow to$2.07 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to the development of stimuli-responsive and nanotechnology-based delivery systems, the expansion of contract research and manufacturing services, regulatory agencies providing incentives and faster approval pathways, and the targeted delivery of biologics and biosimilars. Key trends during this period include advancements in pH-responsive systems, the integration of personalized medicine, the use of AI and digital tools in formulation design, and an increasing focus on oral colon delivery.

The increasing prevalence of gastrointestinal diseases is expected to drive the expansion of the colon targeting drug delivery market. Gastrointestinal diseases, which affect the digestive system including the stomach, intestines, and related organs, are becoming more common due to unhealthy dietary habits, such as high consumption of processed foods and low fiber intake. These habits disrupt gut health and digestion, leading to a rise in conditions such as inflammatory bowel disease (IBD). Colon targeting drug delivery is being used to ensure that drugs are precisely released at the site of inflammation or infection, increasing therapeutic effectiveness and minimizing systemic side effects. For example, in June 2023, Crohn's and Colitis Canada reported that the number of people affected by inflammatory bowel disease is projected to rise from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). This growing prevalence of gastrointestinal diseases is driving demand for colon-targeting drug delivery solutions.

Companies in the colon targeting drug delivery market are focusing on developing advanced solutions that improve targeted drug release, enhance therapeutic efficacy, and reduce side effects. One such innovation is the development of functional oral dosage forms, which are designed to protect active pharmaceutical ingredients (APIs) from degradation in the upper gastrointestinal tract, ensuring their controlled release in the colon. In September 2024, Evonik Industries AG, a Germany-based specialty chemicals company, launched EUDRACAP Functional, a ready-to-fill capsule technology that enables the precise delivery of oral drugs to the colon. This technology uses pH-sensitive polymers that dissolve only at specific intestinal pH levels, ensuring that the API reaches the colon intact. By supporting the oral delivery of complex APIs such as peptides and probiotics, EUDRACAP Functional helps develop patient-friendly therapies for chronic gastrointestinal disorders, offering greater accuracy and reduced systemic exposure.

In October 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Telavant Holding Inc. for $7.1 billion. This acquisition strengthens Roche's position in the colon targeting drug delivery market by integrating Telavant's RVT-3101, a drug aimed at treating inflammatory bowel diseases. Telavant Holding Inc., a US-based biopharmaceutical company, specializes in developing therapies for gastrointestinal disorders. This strategic acquisition enhances Roche's ability to provide innovative treatments for gastrointestinal diseases, further advancing their portfolio in the field of colon-targeting drug delivery.

Major players in the colon targeting drug delivery market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Lonza Pharma AG, Ferring Pharmaceuticals Company Limited, Salix Pharmaceuticals Ltd., Tillotts Pharma AG, BDD Pharma Ltd., and Tharimmune Inc.

North America was the largest region in the colon targeting drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in colon targeting drug delivery report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the colon targeting drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The colon targeting drug delivery market includes revenues earned by entities by providing services such as formulation development, preformulation studies, drug delivery technology licensing, coating and encapsulation services, and in-vitro release testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Colon Targeting Drug Delivery Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on colon targeting drug delivery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for colon targeting drug delivery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The colon targeting drug delivery market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Colon Targeting Drug Delivery Market Characteristics

3. Colon Targeting Drug Delivery Market Trends And Strategies

4. Colon Targeting Drug Delivery Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Colon Targeting Drug Delivery Growth Analysis And Strategic Analysis Framework

6. Colon Targeting Drug Delivery Market Segmentation

7. Colon Targeting Drug Delivery Market Regional And Country Analysis

8. Asia-Pacific Colon Targeting Drug Delivery Market

9. China Colon Targeting Drug Delivery Market

10. India Colon Targeting Drug Delivery Market

11. Japan Colon Targeting Drug Delivery Market

12. Australia Colon Targeting Drug Delivery Market

13. Indonesia Colon Targeting Drug Delivery Market

14. South Korea Colon Targeting Drug Delivery Market

15. Western Europe Colon Targeting Drug Delivery Market

16. UK Colon Targeting Drug Delivery Market

17. Germany Colon Targeting Drug Delivery Market

18. France Colon Targeting Drug Delivery Market

19. Italy Colon Targeting Drug Delivery Market

20. Spain Colon Targeting Drug Delivery Market

21. Eastern Europe Colon Targeting Drug Delivery Market

22. Russia Colon Targeting Drug Delivery Market

23. North America Colon Targeting Drug Delivery Market

24. USA Colon Targeting Drug Delivery Market

25. Canada Colon Targeting Drug Delivery Market

26. South America Colon Targeting Drug Delivery Market

27. Brazil Colon Targeting Drug Delivery Market

28. Middle East Colon Targeting Drug Delivery Market

29. Africa Colon Targeting Drug Delivery Market

30. Colon Targeting Drug Delivery Market Competitive Landscape And Company Profiles

31. Colon Targeting Drug Delivery Market Other Major And Innovative Companies

32. Global Colon Targeting Drug Delivery Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Colon Targeting Drug Delivery Market

34. Recent Developments In The Colon Targeting Drug Delivery Market

35. Colon Targeting Drug Delivery Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기